Experimental drug tested for rare, painful joint tumors
NCT ID NCT04703322
Summary
This study is testing whether the drug pexidartinib is safe and effective for adults in Japan with a rare, non-cancerous joint tumor called tenosynovial giant cell tumor (TGCT). The trial is for people whose symptoms are severe and cannot be improved with surgery. Researchers will measure how the drug affects the tumor size, joint movement, pain, and physical function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanazawa University Hospital
Ishikawa, 920-8641, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital
Aichi, 466-8560, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, 540-0006, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
Conditions
Explore the condition pages connected to this study.